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Table 1
Sex (M/F) 98/102
Median age 51 (18-72)
Age > 50 53%
KPS > 80% 64%
HCT-CI Score >4 19%
Figure 1A. Progression-free survival.
Figure 1B. Cumulative incidence of relapse for FiT3+ve pts by disease status at
transplant.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S82(Table1). All donor sources were included: 63 matched
sibling (MSD), 95 10/10 MUD, 11 9/10 MUD, 18 cord blood
(CB), and 13 haploidentical (Haplo).
Results: The majority of pts received myeloablative condi-
tioning (n¼170; busulfan-based n¼148). Disease status at
AlloSCT was: CR1 (n¼99), CR2 (n¼20), CR with incomplete
count recovery or hypoplasticmarrowor CR3 (CRi; n¼31), and
active disease (AD; n¼50). Thirty percent of pts received a FLT3
inhibitorbeforeAlloSCT.After amedian follow-upof27mo, the
2-year (2Y) OS and PFS rates were 43% and 41%, respectively.
Relapse-related mortality was the main cause of death (68%).
Remission and FLT3 status at the time of AlloSCT were signiﬁ-
cantly associated with PFS. Compared to CR1 pts, PFS was not
different inCR2 [HR1.5, p¼0.3], but itwasworse inCRi (HR3.9,
p<0.001)andADpts (HR5.9, p<0.001). The2YPFSwashighest
inCR1/2FLT3evepts (62%) compared to theothergroups:CR1/
2 FLT3+ve (41%, p¼0.3); CRi FLT3eve (33%, p¼0.01); CRi
FLT3+ve (0%, p<0.001); AD (8% p<0.001) (Figures 1A, 1B). On
multivariate analysis, independent predictors of worse PFS
included: AD [HR 4.5, p<0.001], CRi FLT3+ve [HR 7.2,
p<0.001], KPS80 [HR2.1, p<0.001], HCT-CI>4 [HR 1.6,
p¼0.05], and unrelated donor source [HR 1.6, p¼0.05]. No
difference in PFS was found between Haplo and MSD donor
sources (HR¼0.9, p¼0.9). No signiﬁcant association wasidentiﬁed by age, conditioning intensity or use of a FLT3
inhibitor prior to transplant. Post-transplant FLT3 status was
available for 105 of 190 evaluable pts by day 30. Among
them, 7ptshaddetectable FLT3PCR and5/7 pts (71%) relapsed.
Conclusion: Morphologic remission and FLT3 PCR status at
the time of transplant are key predictors of relapse risk in pts
with FLT3+ AML. Patients who achieved a morphologic CR
with an undetectable FLT3 by PCR at the time of SCT had the
best outcomes and should undergo an AlloSCTwithout delay.
Although the experience is limited, Haplo transplants had
similar outcomes to MSD transplants. Prospective clinical
trials with FLT3 inhibitors post-transplant are warranted at
least for pts with AD or persistent FLT3+ on PCR at transplant.
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Introduction: There are limited data on the impact of he-
matopoietic stem cell transplant (HSCT) conditioning
regimen, especially without total body radiation (TBI) in
pediatric patients with acute lymphoblastic leukemia (ALL)
with central nervous system (CNS) involvement. The aim of
this study is compare the results of HSCT using non-TBI
conditioning regimen in ALL patients aged18 years with or
without CNS involvement.
Patients and Methods: Records of 183 patients with ALL
(128 male; 55 female) with a median age of 14.13.7 years
who had undergone HSCT were studied and classiﬁed in two
groups: with and without CNS involvement. Long-term
consequence of the HSCT consisting of leukemia free survival
(LFS), the overall survival (OS), relapse and transplant-
related mortality (TRM) was compared in the two groups.
Results: A total of 183 ALL patients (148 without CNS
involvement and 35 with CNS involvement) underwent
HSCT in our center using a TBI-free conditioning containing
Busulfan and Cyclophosphomide. The median time of follow
up was 42.1 months. Estimated probability on relapse at 4
year was 51.4% in patients with CNS involvement and 42.1%
in patients without CNS involvement (p¼0.588). Regarding
survival analysis, 4-year OS and LFS in all patients was 44.4%
(SE:2.5%) and 39.7%(SE:2.5%). In multivariate analysis there
were no signiﬁcant differences in OS and LFS between two
groups (p¼0.839, p¼894) nor was there a difference in
relapse probability (HR:1.20, 95%CI:0.69-2.1, p¼0.513) and
TRM (HR:0.44, 95%CI:0.10-1.92, p¼0.286).
Conclusion: HSCT using a non TBI conditioning regimen in
ALL are similar with studies using TBI containing regimens.
Furthermore HSCT leads to similar clinical outcomes and
long-term survival in the ALL pediatric patients with or
without CNS involvement.
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Treatment related mortality n¼80
1-year 15 (8-24)%
2-year 17 (9-26)%
3-year 17 (9-26)%
Disease free survival n¼80
1-year 70 (60-80)%
2-year 62 (50-72)%
3-year 60 (48-71)%
Overall survival n¼84
1-year 78 (69-87)%
2-year 69 (59-79)%
3-year 65 (54-75)%
The 3-year overall survival was 61% (95%CI, 46-74%) in My+B group and 73%
(95%CI, 54-88%) inMy+T group. At three years post transplant, 75%, 48%, and
60% survival rates were observed in younger than 20, 20-40, and older than
40 years age groups, respectively. No notable differences in 3-year overall
survival among those transplanted in CR1 and CR2 (64% and 69%, respec-
tively). Patients with normal/intermediate cytogenetics (n¼44) and those
with bcr/abl+/poor cytogenetics (n¼27) had similar 3-year survival rates:
62% and 70%, respectively. In conclusion, allogeneic transplant is a valid
treatment option for patients with ABiL and should be explored in patients
without signiﬁcant comorbidities. A study in a larger context is planned.
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Introduction: Patients with CLL who relapse after allogeneic
hematopoietic stem cell transplantation (alloHCT) are difﬁ-
cult to treat with chemotherapy due to impaired hemato-
poietic reserve, infections, and concern for graft-versus-host
disease (GVHD). Ibrutinib (Imbruvica) is approved in the
USA for patients with CLL orMCL who have received1 prior
therapy and for patients with CLL with del17p. In preclinical
studies, ibrutinib reversed established chronic GVHD
(cGVHD). We evaluated the safety and efﬁcacy of ibrutinib in
a subset of patients with prior alloHCT.
Methods: Data were collected for R/R patients with prior
alloHCTenrolled in 1 of 4 clinical trials (PCYC-1102, PCYC-1109,
PCYC-1112, and PCYC-1117). PCYC-1112 and PCYC-1117 only
enrolled patients >6 months post-HCT and without GVHD.
Efﬁcacy evaluations included overall response rate (ORR;
iwCLL criteria), duration of response (DOR), progression-free
survival (PFS), and overall survival (OS). Safety evaluations
included adverse events (AEs), including serious AEs (SAEs).
Results: 16 patients from 4 clinical trials had prior alloHCT
(median age, 54.5 y; 16 patients with ECOG performance
status 0 or 1; 10 patients with del17p, 3 with del11q, 12 pa-
tients with 4 prior therapies). Median time since the most
recent HCT was 27 months (range, 8-115). Baseline neu-
tropenia, anemia, and thrombocytopenia were reported in
31%, 25%, and 38%, respectively. Median time on ibrutinib
was 18.1 months (range, 0.4-38.8), with 12 patients being
treated for >12 months. At data cut-off, 11 patients were
continuing treatment. Reasons for discontinuation included
disease progression (n ¼ 2), AEs (n ¼ 2), and consent with-
drawal (n ¼ 1). Investigator-assessed responses included 2
complete responses, 9 partial responses (PRs), and 3 PRswith
lymphocytosis, resulting in a best ORR of 87.5%. Median DOR,
PFS, and OS were not reached at a median follow-up of 23
months. The 24-month PFS and OS rates were 77% and 75%,
respectively. Treatment-emergent grade 3 SAEs were
observed in 11 patients and included infections (n ¼ 6) and
febrile neutropenia, atrial ﬂutter, colitis, perirenal hema-
toma, subdural hematoma, postprocedural hemorrhage, hy-
percalcemia, bone lesion, syncope, hematuria, urinary
retention, and dyspnea (n¼ 1 each; some events reported for
the same patient). The only AE leading to ibrutinib discon-
tinuation was pneumonia (n ¼ 2); both were fatal events.
Two additional deaths occurred on study due to disease
progression at 24 and 28 months.
Conclusion: Ibrutinibwas well tolerated in patients who had
prior alloHCT, with a safety proﬁle similar to that observed in
the overall R/R CLL population. Best ORR (87.5%) is consistent
with results observed in the overall/broader population.
These data support the use of ibrutinib in CLL patients with
prior alloHCT, and its exploration in treatment of cGVHD is
ongoing (NCT 02195869).77
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Acute biphenotypic leukemias (bearing markers of myeloid
and lymphoid origin, ABiL) are rare (2-5% of all acute leuke-
mias) and are considered puzzling both with regard to their
cell of origin aswell as to theoptimal treatment approach. The
diagnostic criteria for ABiL were revised by the World Health
Organization (WHO) in 2008. In the pediatric age group, the
prognosis of ABiL is reported to be intermediate between
acute lymphoblastic and acutemyeloid leukemia. In the adult
age group, ABiL generally has an unfavorable prognosis. As far
as allogeneic transplant for ABiL is concerned, only small se-
ries of cases have been published to date.
In the current study, the CIBMTR database was queried for
patients with ABiL who received an allogeneic transplant
between 1996 and 2013 being younger than 70 years of age
(n¼468). Patients with primary induction failure (n¼19) and
transplanted in relapse (n¼27) were excluded. After detailed
review of pathology, cytogenetic and ﬂow cytometry reports,
of 241 cases submitted as ABiL, those without complete data
to conﬁrm WHO criteria (n¼157) were excluded. Of 84 cases
with complete immunophenotyping data for review, 48 co-
expressed Myeloid and B-lymphoid markers (M+B) and 28
Myeloid and T-lymphoid markers (M+T). The median age of
the patients was 19 years, 56%weremale, themedianWBC at
diagnosis was 17 000, 36% received a bone marrow, 33%
a peripheral blood graft and 31% cord blood stem cells.
The conditioning regimen was myeloablative in 87% and
RIC/NMA in 10% of cases.
Treatment outcomes are shown below:LYMPHOMA/MULTIPLE MYELOMA78
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